摩根大通：将再生元制药公司目标价从540美元上调至559美元

美股研究社2021-07-20

美股研究社讯，美港电讯获悉，摩根大通将再生元制药公司(REGN.O)目标价从540美元上调至559美元。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。该公司的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

MillieZ
2021-07-20
MillieZ
目前股价585，这是要股价往下降吗

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2152717669?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/4ecccb954c9a03cd26d576ebec5c96d6","is_english":false,"pubTime":"2021-07-20 14:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2152717669","market":"us","top_or_hot":-1,"title":"摩根大通：将再生元制药公司目标价从540美元上调至559美元","media":"美股研究社","content":"<div>\n<p>美股研究社讯，美港电讯获悉，摩根大通将再生元制药公司(REGN.O)目标价从540美元上调至559美元。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。该公司的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021072014175879d52675&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>摩根大通：将再生元制药公司目标价从540美元上调至559美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n摩根大通：将再生元制药公司目标价从540美元上调至559美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 14:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021072014175879d52675&s=b><strong>美股研究社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美股研究社讯，美港电讯获悉，摩根大通将再生元制药公司(REGN.O)目标价从540美元上调至559美元。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。该公司的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021072014175879d52675&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021072014175879d52675&s=b","article_id":"2152717669","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/4ecccb954c9a03cd26d576ebec5c96d6"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021072014175879d52675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2152717669","pubTimestamp":1626761820,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美股研究社讯，美港电讯获悉，摩根大通将再生元制药公司(REGN.O)目标价从540美元上调至559美元。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。该公司的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","REGN":"再生元制药公司"},"translate_title":"JPMorgan Chase: Raise the target price of Regeneron Pharmaceuticals from $540 to $559","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"REGN":0.9},"content_text":"美股研究社讯，美港电讯获悉，摩根大通将再生元制药公司(REGN.O)目标价从540美元上调至559美元。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。该公司的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":171780546,"gmtCreate":1626764396385,"gmtModify":1626764396385,"author":{"id":"3557961101904469","authorId":"3557961101904469","name":"MillieZ","avatar":"https://static.tigerbbs.com/c956f9d350d68b1ae5fcb45efecbc52f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3557961101904469","authorIdStr":"3557961101904469"},"htmlText":"目前股价585，这是要股价往下降吗","listText":"目前股价585，这是要股价往下降吗","text":"目前股价585，这是要股价往下降吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171780546","repostId":2152717669,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2152717669"}